St. Joseph Heart Institute, Lexington, KY, USA.
Angiology. 2012 May;63(4):289-96. doi: 10.1177/0003319711414269. Epub 2011 Jul 6.
Stroke remains a major cause of morbidity and mortality worldwide. Despite preventive measures, effective management strategies are needed to reduce the morbidity and mortality associated with this devastating condition. While the management of hemorrhagic stroke is mostly limited to supportive care, reperfusion strategies in ischemic stroke have been developed and continue to evolve. Conceptually, the pathophysiology of ischemic stroke is similar to that of acute myocardial infarction and the objective of management is similar (ie, to rapidly restore normal flow to reduce permanent damage). It is, therefore, not surprising that the management of acute ischemic stroke includes intravenous (IV) thrombolysis, the only Food and Drug Administration (FDA)-approved strategy at this point. In addition, there are a myriad of emerging endovascular interventional techniques. We review the current literature and discuss some of the technical aspects of endovascular therapy in the setting of acute ischemic stroke.
中风仍然是全球范围内发病率和死亡率的主要原因。尽管采取了预防措施，但仍需要有效的管理策略来降低与这种破坏性疾病相关的发病率和死亡率。虽然对出血性中风的治疗主要限于支持性护理，但已开发出并不断发展再灌注策略用于治疗缺血性中风。从概念上讲，缺血性中风的病理生理学与急性心肌梗死相似，管理目标也相似（即快速恢复正常血流以减少永久性损伤）。因此，急性缺血性中风的管理包括静脉内（IV）溶栓治疗也就不足为奇了，这是目前唯一获得美国食品和药物管理局（FDA）批准的策略。此外，还有无数新兴的血管内介入技术。我们回顾了当前的文献，并讨论了急性缺血性中风中血管内治疗的一些技术方面。
